Plain-English translation of NCT04767659 on ClinicalTrials.gov ↗ · Source last updated ·
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new optical imaging device—a special camera that uses near-infrared light—to monitor how breast cancer responds to chemotherapy before surgery. The device is non-invasive and painless, measuring changes in tumor size, blood flow, and oxygen levels during treatment. Doctors hope this tool will help predict which patients will have the best response to chemotherapy, so they can personalize treatment plans.
Currently, doctors rely on standard imaging like ultrasound and MRI to track how chemotherapy is working, but these methods have limitations. This trial aims to develop a faster, safer, and more detailed way to monitor treatment response in real time, which could help doctors decide on the best next steps for surgery and overall care.
You would have optical imaging scans performed at six time points over the course of your chemotherapy—before treatment starts, in the early weeks of treatment, halfway through, and at the end. You'll also receive standard imaging (ultrasound, mammography, and MRI) as part of your regular care. Each optical imaging session is quick, painless, and non-invasive, similar to having a camera placed gently against your breast.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
Italy